| 29.00 Delayed Data As of Sep 20 |  -0.96 / -3.20%Today’s Change | 25.15 Today|||52-Week Range 244.00 | -58.89% Year-to-Date |
| Tilray, Inc. (TLRY) Stock Moves -1.71%: What You Should Know Sep 19 / Zacks.com - Paid Partner Content | Buy Aurora Cannabis (ACB) Stock Before Earnings, Despite Marijuana Volatility? Sep 09 / Zacks.com - Paid Partner Content |
| The Zacks Analyst Blog Highlights: Anheuser-Busch, Tilray, Boston Beer, Constellation Brands and Aphria Sep 16 / Zacks.com - Paid Partner Content | 3 Reasons Why Tilray Can Bounce Back Sep 06 / MotleyFool.com - Paid Partner Content |
| 4 Stocks to Ride on the CBD-Infused Beverage Trend Sep 13 / Zacks.com - Paid Partner Content |
| Previous close | 29.96 |
| Today’s open | 30.23 |
| Day’s range | 28.98 - 31.06 |
| Volume | 1,175,017 |
| Average volume (3 months) | 1,789,366 |
| Market cap | $2.8B |
| Earnings growth (last year) | -873.51% |
| Earnings growth (this year) | -53.55% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +110.00% |
| P/E ratio | NM |
| Price/Sales | 135.76 |
| Price/Book | 13.66 |
| Today’s change | Today’s % change | |
|---|---|---|
| ARWRArrowhead Pharmaceut... | -0.23 | -0.79% |
| CRSPCRISPR Therapeutics ... | +0.82 | +1.73% |
| EBSEmergent BioSolution... | -0.99 | -1.90% |
| IOVAIovance Biotherapeut... | +0.22 | +1.06% |
| Next reporting date | November 12, 2019 |
| EPS forecast (this quarter) | -$0.31 |
| Annual revenue (last year) | $43.1M |
| Annual profit (last year) | -$67.7M |
| Net profit margin | -157.02% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Brendan Kennedy |
Executive Vice President- Operations Greg Christopher |
Corporate headquarters Nanaimo, British Columbia |
